Skip to content
ClinCalc Pro
Menu
Antifibrinolytic (Gynaecological Use)

Tranexamic Acid (Heavy Menstrual Bleeding)

Brand names: Cyklokapron, Urimex

Tranexamic acid is an antifibrinolytic used as a first-line non-hormonal treatment for heavy menstrual bleeding, taken orally only during menstruation.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It competitively inhibits the activation of plasminogen to plasmin, reducing clot breakdown in the endometrium and thereby decreasing menstrual blood loss.

Prescribing in practice

  • It is contraindicated in active thromboembolic disease and used with caution where there is a personal or strong family history of venous thromboembolism.
  • It is taken only on the days of heavy bleeding and is a suitable choice for women who wish to avoid hormonal treatment or who are trying to conceive.
  • Gastrointestinal upset is the commonest adverse effect, and it does not provide contraception.

Monitoring

Monitoring is by clinical response; review if bleeding does not improve after a few menstrual cycles to reconsider the diagnosis and treatment.

Counselling the patient

  • Take it only during your period on the heavy-bleeding days, as directed.
  • It reduces bleeding but does not act as a contraceptive or treat pain.
  • Stop and seek advice if you develop calf pain or swelling, breathlessness, or visual disturbance.

Evidence & guidelines

NICE recommends tranexamic acid as a first-line non-hormonal option for heavy menstrual bleeding.

Reference: NICE NG88 (Heavy Menstrual Bleeding 2018); WOMAN trial (Shakur et al. Lancet 2017 — PPH context); MHRA guidance on VTE and tranexamic acid; SPC Cyklokapron; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.